Research Projects & Grants

For Profit Organization

• J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence, Role: Investigator, Eli Lilly & Co., (05/2025 - 05/2026) Status: Approved
• SDX-0103: A Phase 1b/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with a PI3K Pathway Inhibitor plus Fulvestrant in Men and Postmenopausal Women with Advanced Breast Cancer and PI3K Pathway Alterations Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor, Role: Investigator, SynDevRx, Inc., (01/2026 - 01/2027) Status: Approved
• TCBIO-001-0710: The Caris Biorepository Research Protocol, Role: Investigator, Caris MPI, Inc., (04/2026) Status: Approved
• RASolve 301: Phase 3 Multicenter, Open Label, Randomized Study of RMC-6236 versus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic RAS (MUT) NSCLC, Role: Investigator, Revolution Medicines, Inc., (01/2026 - 01/2027) Status: Approved

Internal

• Investigator initiated CIPNGRASP: A pilot study of intraneural facilitation for managing chemotherapy-induced peripheral neuropathy, Role: Investigator, LLU Dept. of Medicine, (03/2026 - 03/2027) Status: Approved